EUVIMEDEUVIMED entdecken
Crossref

Effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease

Donna S-H Lin, Jen-Kuang Lee, Kuan-Chih Huang, Ting-Tse Lin, Hao-Yun Lo

Diabetologia · 2024

DOI: 10.1007/s00125-024-06257-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetologia, 2024. Verfasst von Donna S-H Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Glomerular Filtration Rate. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS/HYPOTHESIS: Although the benefits of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in chronic kidney disease (CKD) are well established, the effects of these therapeutic agents in patients with advanced CKD are less certain. We hypothesised that the continued use of these drugs, even when renal function deteriorates to stage 4 CKD or worse, is safe and associated with improved cardiorenal survival. METHODS: This is a retrospective cohort study utilising data from medical records from two institutions. All patients with type 2 diabetes mellitus who were prescribed an SGLT2i between 1 January 2016 and 31 December 2021, who subsequently had eGFR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Renal Insufficiency, ChronicGlomerular Filtration RateHumansMaleFemaleRetrospective StudiesMiddle AgedAgedKidneyCardiovascular Diseases

Stichwörter der Autor:innen

Chronic kidney diseaseDiabetesDialysisMajor adverse cardiovascular eventsRenal protectionSodium–glucose cotransporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
  • Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Laboratory Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Cardiovascular Center, National Taiwan University Hospital, Taipei, Taiwan.
  • Telehealth Center, National Taiwan University Hospital, Taipei, Taiwan.

Förderung

  • National Science and Technology Council

Zitieren

APA

Lin, D. S., Lee, J. K., Huang, K. C., Lin, T. T., & Lo, H. Y. (2024). Effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease. Diabetologia. https://doi.org/10.1007/s00125-024-06257-7

Vancouver

Lin DS, Lee JK, Huang KC, Lin TT, Lo HY. Effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease. Diabetologia. 2024. doi:10.1007/s00125-024-06257-7

BibTeX
@article{Lin2024,
  author = {Lin, Donna S-H and Lee, Jen-Kuang and Huang, Kuan-Chih and Lin, Ting-Tse and Lo, Hao-Yun},
  title = {Effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease},
  journal = {Diabetologia},
  year = {2024},
  doi = {10.1007/s00125-024-06257-7}
}
Kostenlos starten →